The European Society of Endocrinology (ESE) has published a Revised Clinical Practice Guideline for the Treatment of Chronic ...

The European Society of Endocrinology (ESE) has published an open access Revised Clinical Practice Guideline for the ...

In both trials, TransCon PTH was generally well tolerated, with no new safety signals identified. Most treatment-emergent adverse events (TEAEs) were mild to moderate (Grade 1 or 2) and no patients ...

Hypoparathyroidism is a rare endocrine disorder caused by insufficient or absent secretion of parathyroid hormone, leading to hypocalcemia, hyperphosphatemia, and a range of neuromuscular and renal ...

Please provide your email address to receive an email when new articles are posted on . Most adults with hypoparathyroidism had normalized calcium levels without needing a supplement after 3 months of ...

Adults with nonsurgical hypoparathyroidism are more likely to have worse arterial stiffness, higher heart rate and higher LDL cholesterol patients with pseudohypoparathyroidism, increasing the risk ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window After rejecting ...

Older people treated for Graves disease with total thyroidectomy in the United States are at low risk of developing hypoparathyroidism, according to results from a large population-based cohort study.

September 22, 2011 (San Diego, California) — Parathyroid hormone (PTH) (1-84) is a safe and effective treatment for hypoparathyroidism for up to 4 years, according to research presented here at the ...

MBX Biosciences, Inc. ( (MBX) ) has shared an announcement.

Revised Guideline published 10 years after original Guideline, key differences include redefinition and practical treatment ...